Description

Brilacidin is a synthetic, non-peptidic small-molecule antimicrobial agent with a unique mechanism of action targeting bacterial membranes. It offers potent broad-spectrum activity against multidrug-resistant Gram-positive and Gram-negative pathogens while demonstrating low propensity for resistance development. This compound is critically valued by pharmaceutical R&D laboratories, contract development and manufacturing organizations (CDMOs), and biotech innovators advancing next-generation anti-infective therapeutics. Brilacidin CAS NO 1224095-98-0 is supplied as a high-purity research-grade active pharmaceutical ingredient (API) candidate for preclinical and clinical-stage development.

Application

• Preclinical development of novel antibiotics targeting drug-resistant bacteria (e.g., MRSA, VRE, Pseudomonas aeruginosa)
• Formulation studies for topical, inhaled, and intravenous delivery systems
• Structure–activity relationship (SAR) and medicinal chemistry optimization programs
• Mode-of-action and membrane permeabilization mechanistic studies
• Combination therapy screening with conventional antibiotics to overcome resistance
• GMP-compatible process development and analytical method validation
• Reference standard for pharmacokinetic and toxicokinetic assays
• Antibiofilm activity evaluation in chronic wound and cystic fibrosis models

Basic Information

Product Name	Brilacidin
CAS No.	1224095-98-0
Molecular Formula	C36H45ClN6O6
Molecular Weight	701.25 g/mol
Synonyms	Brilacidin; PMX-30063; PMX-30063-00; N,N'-Bis[(4-chlorophenyl)methyl]-N,N'-bis[2-(2-hydroxyethoxy)ethyl]ethane-1,2-diamine dihydrochloride; 1,2-Ethanediamine, N,N'-bis[(4-chlorophenyl)methyl]-N,N'-bis[2-(2-hydroxyethoxy)ethyl]-, dihydrochloride; Brilacidin dihydrochloride; PMX-30063 dihydrochloride; NSC-758250
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. Certificates of Analysis (COA) are available upon request. All batches meet stringent specifications for identity, assay, residual solvents, heavy metals, and microbial limits — fully aligned with ICH Q5, Q6A, and Q7 guidelines for pharmaceutical intermediates and API candidates. Testing includes HPLC purity ≥ 98.5%, chiral purity > 99.0% ee, and full spectral confirmation (IR, 1H-NMR, MS). Complies with REACH and FDA requirements for research-use-only (RUO) and investigational new drug (IND)-enabling material.

Storage

Preserve in a tightly closed container, protected from light. Store at 2–8°C under inert atmosphere (nitrogen or argon) due to hygroscopic and light-sensitive nature. Keep desiccated; avoid exposure to ambient humidity. Handle in a controlled environment with low moisture content (<30% RH) and minimal light exposure.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	98.5% – 101.0%
Related Substances (HPLC)	Single impurity ≤ 0.3%; Total impurities ≤ 1.5%
Residual Solvents (GC)	Meets ICH Q3C Class 3 limits
Water (Karl Fischer)	≤ 1.0%
Heavy Metals	≤ 10 ppm
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.